Elimination of false-negative hepatitis C virus RNA results by removal of inhibitors in cadaver-organ donor blood specimens

Transplantation

Volumn 76, Issue 2, 2003, Pages 432-434

  Padley, David J ^a   Lucas, Sebastian B ^b   Saldanha, John ^c  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c NIBSC ^*

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEIC ACID; RNA; RNA DIRECTED DNA POLYMERASE; VIRUS ANTIBODY; VIRUS RNA;

ARTICLE; BLOOD SAMPLING; CADAVER DONOR; CONTROLLED STUDY; DNA EXTRACTION; ENZYME INHIBITION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NORMAL HUMAN; ORGAN DONOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSPLANTATION; VIRUS DETECTION; VIRUS INFECTION;

CADAVER; FALSE NEGATIVE REACTIONS; HEPACIVIRUS; HEPATITIS C; HUMANS; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TISSUE DONORS;

EID: 0042266718     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000072780.66347.B1     Document Type: Article

References (10)

1. Stanworth S, Warwick R, Ferguson M, et al. A UK survey of virological testing of cadaver tissue donors. Microbiology Working Group of the NIBSC Steering Group of Tissue/Cell Banking and Tissue Banking in UK: microbiological testing of tissue donors. Vox Sang 2000; 79: 227.
2. Busch M, Lee L, Satten G, et al. Time course of detection of viral and serological markers preceding human immunodeficiency virus type 1 seroconversion: implication for screening of blood and tissue donors. Transfusion 1995; 35: 91.
3. Conrad E, Gretch D, Obermeyer K, et al. The transmission of hepatitis C virus by tissue transplantation. J Bone Joint Surg 1995; 77-A: 214.
4. Eastlund T. Infectious disease transmission through cell, tissue and organ transplantation: reducing the risk through donor selection. Cell Transplant 1995; 4: 445.
5. Kleinman S, Busch M, Korelitz J, et al. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev 1997; 11: 15.
6. Nübling M, Seitz R, Löwer J. Application of nucleic acid amplification techniques for blood donation screening. Infusionther Transfus Med 1998; 25: 86.
7. Burtonboye G, Delloye C. Polymerase chain reaction in cadaveric blood and tissues. Transplant Proc 1996; 28: 2927.
8. Saldanha J, Lelie N, Heath A, and the WHO Collaborative Study Group. Establishment of the first international standard for nucleic acid amplification technology NAT) assays for HCV RNA. Vox Sang 1999; 76: 149.
9. Miédougé M, Chatelut M, Mansuy J-M, et al. Screening of blood from potential organ and cornea donors for viruses. J Med Virol 2002; 66: 571.
10. Committee for Proprietary Medicinal Products. Introduction of genomic amplification technology (GAT) for the detection of hepatitis C virus RNA in plasma pools. Addendum for guidance on plasma derived products 1997. London: The European Agency for the Evaluation of Medicinal Products. CPMP/BWP/390/97.